Literature DB >> 21478833

Pharma interest surges in antibody drug conjugates.

Sarah Webb.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21478833     DOI： 10.1038/nbt0411-297

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Antibody-drug conjugates for cancer: poised to deliver?

Authors:  Bethan Hughes
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694
  1 in total
  16 in total

Review 1.  Optimising the delivery of tubulin targeting agents through antibody conjugation.

Authors:  Gary D Stack; John J Walsh
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

2.  Site-specific chemical modification of antibody fragments using traceless cleavable linkers.

Authors:  Gonçalo J L Bernardes; Martina Steiner; Isabelle Hartmann; Dario Neri; Giulio Casi
Journal:  Nat Protoc       Date:  2013-10-03       Impact factor: 13.491

3.  Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016).

Authors:  Yunfeng Lai; Ruibing Wang; Xin Chen; Daisheng Tang; Yuanjia Hu; Jing Cai; Qingwen Zhang; Hao Hu
Journal:  Hum Vaccin Immunother       Date:  2017-02-21       Impact factor: 3.452

4.  Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.

Authors:  Seth H Pincus; Kejing Song; Grace A Maresh; Anderson Frank; David Worthylake; Hye-Kyung Chung; Patricia Polacino; Dean H Hamer; Cody P Coyne; Michael G Rosenblum; John W Marks; Gang Chen; Deborah Weiss; Victor Ghetie; Ellen S Vitetta; James E Robinson; Shiu-Lok Hu
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

Review 5.  Aptamer-based targeted therapy.

Authors:  Guizhi Zhu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-08-17       Impact factor: 15.470

Review 6.  Aptamer-Drug Conjugates.

Authors:  Guizhi Zhu; Gang Niu; Xiaoyuan Chen
Journal:  Bioconjug Chem       Date:  2015-07-14       Impact factor: 4.774

7.  Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.

Authors:  Alison M Betts; Nahor Haddish-Berhane; John Tolsma; Paul Jasper; Lindsay E King; Yongliang Sun; Subramanyam Chakrapani; Boris Shor; Joseph Boni; Theodore R Johnson
Journal:  AAPS J       Date:  2016-05-19       Impact factor: 4.009

8.  Detection of complement activation using monoclonal antibodies against C3d.

Authors:  Joshua M Thurman; Liudmila Kulik; Heather Orth; Maria Wong; Brandon Renner; Siranush A Sargsyan; Lynne M Mitchell; Dennis E Hourcade; Jonathan P Hannan; James M Kovacs; Beth Coughlin; Alex S Woodell; Matthew C Pickering; Bärbel Rohrer; V Michael Holers
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

9.  Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.

Authors:  Dhaval K Shah; Nahor Haddish-Berhane; Alison Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-15       Impact factor: 2.745

Review 10.  Nucleic acid aptamers: an emerging frontier in cancer therapy.

Authors:  Guizhi Zhu; Mao Ye; Michael J Donovan; Erqun Song; Zilong Zhao; Weihong Tan
Journal:  Chem Commun (Camb)       Date:  2012-11-04       Impact factor: 6.222
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.